Cargando…
PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430174/ http://dx.doi.org/10.1097/01.HS9.0000974360.24047.92 |
| _version_ | 1785090894445150208 |
|---|---|
| author | Arnan, Montserrat Montesinos, Pau de Botton, Stéphane Recher, Christian Wunderle, Lydia Emig, Michael Harstrick, Andreas Pietzko, Kerstin Pinto, Sheena Ravenstijn, Paulien Daver, Naval |
| author_facet | Arnan, Montserrat Montesinos, Pau de Botton, Stéphane Recher, Christian Wunderle, Lydia Emig, Michael Harstrick, Andreas Pietzko, Kerstin Pinto, Sheena Ravenstijn, Paulien Daver, Naval |
| author_sort | Arnan, Montserrat |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430174 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104301742023-08-17 PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) Arnan, Montserrat Montesinos, Pau de Botton, Stéphane Recher, Christian Wunderle, Lydia Emig, Michael Harstrick, Andreas Pietzko, Kerstin Pinto, Sheena Ravenstijn, Paulien Daver, Naval Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430174/ http://dx.doi.org/10.1097/01.HS9.0000974360.24047.92 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Arnan, Montserrat Montesinos, Pau de Botton, Stéphane Recher, Christian Wunderle, Lydia Emig, Michael Harstrick, Andreas Pietzko, Kerstin Pinto, Sheena Ravenstijn, Paulien Daver, Naval PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) |
| title | PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) |
| title_full | PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) |
| title_fullStr | PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) |
| title_full_unstemmed | PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) |
| title_short | PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML) |
| title_sort | pb1884: engaging innate immunity: a phase 1 dose escalation study to assess safety and tolerability of afm28 monotherapy in patients with relapsed/refractory cd123-positive acute myeloid leukemia (aml) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430174/ http://dx.doi.org/10.1097/01.HS9.0000974360.24047.92 |
| work_keys_str_mv | AT arnanmontserrat pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT montesinospau pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT debottonstephane pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT recherchristian pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT wunderlelydia pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT emigmichael pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT harstrickandreas pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT pietzkokerstin pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT pintosheena pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT ravenstijnpaulien pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml AT davernaval pb1884engaginginnateimmunityaphase1doseescalationstudytoassesssafetyandtolerabilityofafm28monotherapyinpatientswithrelapsedrefractorycd123positiveacutemyeloidleukemiaaml |